Australia's most trusted
source of pharma news
Posted 16 February 2026 PM
Chimeric Therapeutics has appointed experienced biotech executive and cell therapy specialist, Dr Bradley Glover, as Non-Executive Chair following a global recruitment process that identified over 30 potential candidates.
The appointment marks roughly three months since the cell therapy company announced it would prioritise a Board refresh after it received “substantial feedback” from shareholders, including its largest institutional backer, on a range of governance and operational matters following its Annual General Meeting where Chimeric’s founder and Executive Chairman, Paul Hopper, announced his retirement.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.